Industry Strength Score
56/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
ROCKET PHARMACEUTICALS INC (RCKT) Stock Price & Overview
NASDAQ:RCKT • US77313F1066
Current stock price
3.48 USD
0 (0%)
At close:
3.5248 USD
+0.04 (+1.29%)
Pre-Market:
The current stock price of RCKT is 3.48 USD. Today RCKT is down by 0%. In the past month the price decreased by -3.87%. In the past year, price decreased by -56.55%.
RCKT Key Statistics
52-Week Range2.19 - 8.19
Current RCKT stock price positioned within its 52-week range.
1-Month Range3.31 - 4.1
Current RCKT stock price positioned within its 1-month range.
- Market Cap
- 379.738M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.98
- Dividend Yield
- N/A
RCKT Stock Performance
Today
0%
1 Week
-5.43%
1 Month
-3.87%
3 Months
N/A
Longer-term
6 Months -7.69%
1 Year -56.55%
2 Years -83.83%
3 Years -80.58%
5 Years -92.41%
10 Years N/A
RCKT Stock Chart
RCKT Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to RCKT. When comparing the yearly performance of all stocks, RCKT is a bad performer in the overall market: 89.45% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
RCKT Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to RCKT. Both the profitability and financial health of RCKT have multiple concerns.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
RCKT Earnings
Next Earnings DateMay 11, 2026
Last Earnings DateFeb 26, 2026
PeriodQ4 / 2025
EPS Reported-$0.38
Revenue Reported
EPS Surprise 17.82%
Revenue Surprise %
RCKT Forecast & Estimates
20 analysts have analysed RCKT and the average price target is 8.65 USD. This implies a price increase of 148.47% is expected in the next year compared to the current price of 3.48.
Analysts
Analysts73
Price Target8.65 (148.56%)
EPS Next Y25.77%
Revenue Next YearN/A
RCKT Index Membership
RCKT is currently included in the following stock indexes tracked on ChartMill.
RCKT Financial Highlights
Over the last trailing twelve months RCKT reported a non-GAAP Earnings per Share(EPS) of -1.98. The EPS increased by 27.47% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-223.12M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -67.52% | ||
| ROE | -80.49% | ||
| Debt/Equity | 0.07 |
Chartmill High Growth Momentum
EPS Q2Q%38.71%
Sales Q2Q%N/A
EPS 1Y (TTM)27.47%
Revenue 1Y (TTM)N/A
RCKT Ownership
Ownership
Inst Owners85.92%
Shares109.12M
Float105.87M
Ins Owners4.15%
Short Float %18.02%
Short Ratio5.2
RCKT Industry Overview
RCKT operates in the Biotechnology sub-industry within the Health Care sector. This group contains 416 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
13/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
27%
Outperformed 27% of sub-industries
3 Month Rank
47%
Outperformed 47% of sub-industries
6 Month Rank
30%
Outperformed 30% of sub-industries
Industry Fundamentals & Breadth
- Members
- 416
- New Highs
- 4.1%
- New Lows
- 4.6%
- Average ROE
- 48.3%
- Average Profit Margin
- 20.7%
- Average Operating Margin
- 33.6%
- Average P/E
- 26.4
- Average Fwd P/E
- 22.3
- Average Debt/Equity
- 2.2
RCKT Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.88 | 373.774B | ||
| AMGN | AMGEN INC | 14.57 | 186.868B | ||
| GILD | GILEAD SCIENCES INC | 14.8 | 162.401B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.94 | 108.708B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.82 | 74.75B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 28.78 | 41.295B | ||
| INSM | INSMED INC | N/A | 29.427B | ||
| NTRA | NATERA INC | N/A | 29.219B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.56B | ||
| BIIB | BIOGEN INC | 11.58 | 27.779B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.55 | 25.042B | ||
| INCY | INCYTE CORP | 10.43 | 18.96B | ||
| MRNA | MODERNA INC | N/A | 18.219B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About RCKT
Company Profile
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. The company is headquartered in Cranbury, New Jersey and currently employs 202 full-time employees. The company went IPO on 2015-02-18. The firm has two clinical stage and one pre-clinical stage in vivo adeno-associated viral (AAV) programs in the United States, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is the most common form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart resulting in enlarged heart chambers that are unable to pump blood.
Company Info
IPO: 2015-02-18
ROCKET PHARMACEUTICALS INC
9 Cedarbrook Drive
Cranbury NEW JERSEY 08512 US
CEO: Gaurav Shah
Employees: 202
Phone: 16464409100
ROCKET PHARMACEUTICALS INC / RCKT FAQ
What does RCKT do?
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. The company is headquartered in Cranbury, New Jersey and currently employs 202 full-time employees. The company went IPO on 2015-02-18. The firm has two clinical stage and one pre-clinical stage in vivo adeno-associated viral (AAV) programs in the United States, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is the most common form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart resulting in enlarged heart chambers that are unable to pump blood.
Can you provide the latest stock price for ROCKET PHARMACEUTICALS INC?
The current stock price of RCKT is 3.48 USD.
What is the dividend status of ROCKET PHARMACEUTICALS INC?
RCKT does not pay a dividend.
What is the ChartMill rating of ROCKET PHARMACEUTICALS INC stock?
RCKT has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What sector and industry does ROCKET PHARMACEUTICALS INC belong to?
ROCKET PHARMACEUTICALS INC (RCKT) operates in the Health Care sector and the Biotechnology industry.
What is the employee count for RCKT stock?
ROCKET PHARMACEUTICALS INC (RCKT) currently has 202 employees.
Who owns ROCKET PHARMACEUTICALS INC?
You can find the ownership structure of ROCKET PHARMACEUTICALS INC (RCKT) on the Ownership tab.